Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $131,939.93 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the business's stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $19.79, for a total value of $131,939.93. Following the transaction, the chief operating officer directly owned 296,642 shares in the company, valued at $5,870,545.18. The trade was a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Monday, June 9th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.34, for a total value of $135,606.78.
• On Wednesday, May 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.39, for a total value of $122,606.13.

Enliven Therapeutics Price Performance

ELVN traded down $0.33 during trading on Friday, hitting $22.45. The stock had a trading volume of 343,523 shares, compared to its average volume of 301,548. The company has a 50 day moving average price of $19.77 and a 200-day moving average price of $20.30. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -11.69 and a beta of 0.83. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ELVN. The Goldman Sachs Group began coverage on Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price on the stock. Jones Trading reduced their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Robert W. Baird boosted their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Finally, HC Wainwright boosted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $41.20.

Institutional Trading of Enliven Therapeutics

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares during the period. GAMMA Investing LLC lifted its position in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares during the period. Quantbot Technologies LP bought a new stake in shares of Enliven Therapeutics during the 1st quarter valued at $60,000. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $97,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $112,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.